<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis of systemic sclerosis (scleroderma)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis of systemic sclerosis (scleroderma)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis of systemic sclerosis (scleroderma)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Denton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John S Axford, DSc, MD, FRCP, FRCPCH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The pathogenesis of systemic sclerosis (SSc; scleroderma) is complex and remains incompletely understood. Immune activation, vascular damage, and excessive synthesis of extracellular matrix with deposition of increased amounts of structurally normal collagen are all known to be important in the development of this illness [<a href="#rid1">1,2</a>]. These mechanisms result from cell-cell, cell-cytokine, and cell-matrix interactions. The heterogeneity in the clinical features of patients with SSc is most likely a reflection of the variable contributions from each of these pathogenic factors.</p><p>Most hypotheses of the pathogenesis of SSc focus on the interplay between early immunological events and vascular changes, which result in the generation of a population of activated fibrogenic fibroblasts generally considered to be the effector cell in the disease (<a class="graphic graphic_figure graphicRef53253" href="/z/d/graphic/53253.html" rel="external">figure 1</a>) [<a href="#rid2">2-4</a>]. There is no doubt that vascular and immunologic processes are central to the pathogenesis of scleroderma, although it is unclear what the initial events are and how different processes respectively trigger, amplify, and facilitate the development of the skin- and organ-based fibrosis with vasculopathy that is the hallmark of the disease.</p><p>Considering the clinical differences between scleroderma and other autoimmune rheumatic diseases and the relatively modest effects that have been observed in clinical trials of immunosuppressive agents (eg, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>), it is perhaps surprising that genetic and serologic approaches to understanding scleroderma pathogenesis have highlighted the importance of cellular and humoral immunity. Many of the genetic loci associated with scleroderma susceptibility in large-scale genetic analyses are also associated with systemic lupus and other autoimmune conditions [<a href="#rid5">5</a>]. Moreover, even when non-immune genes are associated in subphenotype analyses of genetic loci, these associations are often defined by hallmark scleroderma autoantibodies [<a href="#rid6">6</a>], again supporting the key role of the immune system in the development and clinical features of the disease.</p><p>The multiple factors felt to be involved in the pathogenesis of SSc are reviewed here. The possible causes of SSc, as well as the clinical manifestations, diagnosis, and treatment of this disorder, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7557.html" rel="external">"Risk factors for and possible causes of systemic sclerosis (scleroderma)"</a> and  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">VASCULAR AND ENDOTHELIAL CHANGES</span><span class="headingEndMark"> — </span>Vascular and endothelial cell changes, primarily mediating vascular tone, appear to precede other features of systemic sclerosis (SSc).</p><p class="headingAnchor" id="H3"><span class="h2">Vasoconstriction</span><span class="headingEndMark"> — </span>The following mediators of vascular tone may be important in the pathogenesis of SSc [<a href="#rid7">7-9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Endothelins (ETs)</p><p class="bulletIndent1"><span class="glyph">●</span>Nitric oxide (NO, or endothelium-derived relaxing factor)</p><p class="bulletIndent1"><span class="glyph">●</span>Endothelium-derived constricting factors (EDCF)</p><p class="bulletIndent1"><span class="glyph">●</span>Neural, humoral, and inflammatory mediators</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoxia</p><p class="bulletIndent1"><span class="glyph">●</span>Physical stress</p><p></p><p>Derangements of endothelins, NO, and superoxide anions (which are inflammatory mediators) are felt to be the most significant mediators of altered vascular tone in SSc.</p><p class="headingAnchor" id="H4"><span class="h3">Endothelin</span><span class="headingEndMark"> — </span>ET-1, a potent vasoconstrictor, is also fibrogenic and is potentially of great importance in the pathogenesis of SSc [<a href="#rid8">8</a>]. The following observations are consistent with this hypothesis:</p><p class="bulletIndent1"><span class="glyph">●</span>ET-1 may contribute both to vascular dysfunction and to the development of the fibrotic lesion in SSc [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The basal secretion of ET-1 from the endothelial cell may provide an important early link between endothelial cell damage and fibroblast activation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significantly elevated circulating levels of ET-1 have been found both in the minimally fibrotic subset of SSc patients with primary vascular disease and associated pulmonary hypertension and in the diffuse fibrotic subset in whom widespread fibrosis is the major hallmark of the disease [<a href="#rid11">11-13</a>].</p><p></p><p>ET-1 may play an important role in the initiation of fibrosis in SSc as suggested by immunohistochemical and autoradiographic studies. ET-1 has been found in association with the following structures using these special techniques [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Superficial vessels in both clinically involved and uninvolved skin.</p><p class="bulletIndent1"><span class="glyph">●</span>Its putative receptor, to which it is bound, in the "yet to be involved" skin. This binding decreased with increasing tissue fibrosis.</p><p></p><p class="headingAnchor" id="H5"><span class="h3">Nitric oxide</span><span class="headingEndMark"> — </span>NO balances the vasoconstrictive action of ET-1 in normal blood vessels; a change in the relative amounts of these two compounds is postulated to play a pathogenic role in SSc. However, conflicting data exist concerning the role of nitric oxide. In a preliminary study, total NO-producing compounds were decreased in the plasma of patients with SSc [<a href="#rid15">15</a>]; furthermore, the increase in plasma NO seen after exposure of normal subjects to a cold challenge was absent in these patients. In addition, levels of exhaled nitric oxide correlated inversely with the severity of elevation of pulmonary artery pressure in patients with SSc lung disease [<a href="#rid16">16</a>]. In another study, however, levels of plasma NO were significantly elevated in SSc patients compared with those in controls [<a href="#rid17">17</a>].</p><p>NO synthase (NOS) is present in some neurons, as well as within endothelial cells. A progressive decline in cutaneous neurons containing NOS has been noted in patients with diffuse and limited SSc; however, it is uncertain whether this is a cause or a result of diminished tissue perfusion [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Superoxide anions</span><span class="headingEndMark"> — </span>Superoxide anions released from the endothelium may damage the endothelium by being able to neutralize NO and by oxidizing circulating low-density lipoproteins (LDLs). Oxidized LDLs may be the source of the cytotoxicity of stored SSc serum on cultured endothelial cells [<a href="#rid19">19</a>]. Studies have shown that LDLs in patients with SSc are much more susceptible to oxidation (perhaps via free radical attack) than are those from patients with primary Raynaud phenomenon or other rheumatic diseases [<a href="#rid20">20</a>]. In addition, increased urinary and serum levels of markers of oxidative free radical injury (F2-isoprostanes and 8-isoprostane, respectively) have been found in patients with SSc when compared with healthy controls [<a href="#rid21">21,22</a>].</p><p>One adverse effect of superoxide anions, inactivation of NO, has been mentioned above. Another is nitrosylation of proteins by peroxynitrite, a product of the reaction of NO and superoxide. Significantly increased concentrations of nitrosylated proteins have been noted in the plasma of patients with diffuse skin involvement but have not been noted in those with limited skin disease or in people with primary Raynaud phenomenon [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Defective vasculogenesis</span><span class="headingEndMark"> — </span>A deficiency of circulating endothelial cell precursors and a defect in the ability of such cells to proliferate and mature into endothelial cells may be an important pathogenic mechanism in SSc. Preliminary evidence suggests that there are significantly fewer circulating endothelial cell precursors in such patients than in healthy controls or in those with rheumatoid arthritis [<a href="#rid24">24</a>]. In addition, cells with surface markers typically associated with a vasculogenic potential (ie, CD34+CD133+ and vascular endothelial growth factor type 2 bearing) that are present in SSc patients less often differentiate into endothelial cells in culture than cells with the same markers obtained from controls.</p><p class="headingAnchor" id="H8"><span class="h1">VASCULAR CYTOTOXIC FACTORS</span><span class="headingEndMark"> — </span>The sera from some patients with systemic sclerosis (SSc) have been found to be cytotoxic to endothelial cells. The following antibodies, cytokines, proteases, and complement factors may be responsible for this activity:</p><p class="bulletIndent1"><span class="glyph">●</span>Twenty to 30 percent of patients with SSc have circulating antiendothelial cell antibodies. These antibodies by themselves are not thought to be critical, since they are found in the sera of patients with other rheumatic diseases. However, they are capable of upregulating the expression of adhesion molecules on endothelial cells and (in in vitro and in vivo animal experiments) of inducing apoptosis of these cells [<a href="#rid25">25-28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The vascular cytotoxicity of some SSc sera is blocked by monoclonal antibodies to tumor necrosis factor (TNF)-alpha or -beta.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The activity of some SSc sera is blocked by prior incubation with protease inhibitors. The source of these proteases and their nature are unknown, but retroviral proteases and the granzyme family of proteases produced by activated T cells are thought to be possible candidates [<a href="#rid29">29</a>]. Proteolytic activity of granzymes may also degrade angiogenic plasmin and may increase the levels of angiostatin [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Deposition of the complement membrane attack complex (C5b-C9) has been demonstrated immunohistochemically in the microvasculature of involved skin of patients with early and late SSc [<a href="#rid31">31</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h1">ADHESION MOLECULES</span><span class="headingEndMark"> — </span>Adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) are upregulated in response to cytokines and other factors following inflammation and damage to the vascular endothelium. These endothelial adhesion molecules bind to specific integrins on T and B cells, neutrophils, monocytes, natural killer (NK) cells, and platelets [<a href="#rid32">32</a>]. This interaction results in adhesion and subsequent migration of these cells through leaky endothelium and into the extracellular matrix. (See  <a class="medical medical_review" href="/z/d/html/3983.html" rel="external">"Leukocyte-endothelial adhesion in the pathogenesis of inflammation"</a>.)</p><p>Patients with systemic sclerosis (SSc) have both an increase in endothelial cell surface expression of adhesion molecules and an elevation in circulating levels of their soluble forms [<a href="#rid33">33</a>], as shown in the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>Positive immunostaining for E-selectin and ICAM-1 has been demonstrated on endothelial cells in SSc skin but not in control skin [<a href="#rid34">34-36</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Increased circulating levels of E-selectin, VCAM-1, and ICAM-1 have also been observed in small cross-sectional studies of patients with SSc [<a href="#rid17">17,37,38</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated levels of soluble VCAM-1, E-selectin, and ICAM-1 were found in patients with SSc renal crisis, but not in those with SSc-associated pulmonary disease [<a href="#rid39">39</a>].</p><p></p><p>It is unlikely that a single measurement will be of particular clinical use or predictive value. However, one study of serial serum samples has indicated a correlation between changes in soluble VCAM-1 and in soluble E-selectin and clinical deterioration or improvement [<a href="#rid40">40</a>]. Such serial studies need to be expanded, as proven markers for disease activity are not available but are urgently required.</p><p>Increased expression of messenger ribonucleic acid (mRNA) for some adhesion molecules in the peripheral blood cells of patients with SSc may lead to novel diagnostic tests for SSc. Upregulated expression of genes that encode ligands for P-selectin (SELPLG gene) and receptors for von Willebrand factor (ITGA2B and GP1BB genes) are among a total of 382 differentially regulated genes identified in a study that utilized gene expression profiling of unseparated peripheral blood cells to distinguish between SSc patients and healthy controls [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H10"><span class="h1">IMMUNOLOGIC ACTIVITY</span><span class="headingEndMark"> — </span>The continuing activation of endothelial cells, resulting in the upregulation of adhesion molecules, leukocyte adhesion, and leukocyte migration out of the vasculature, probably contributes to the pathogenesis of systemic sclerosis (SSc). It is likely that both innate immunity and adaptive immunity are perturbed in SSc and share a role in pathogenesis. The following studies support this conclusion:</p><p class="bulletIndent1"><span class="glyph">●</span>The expression of endothelial leukocyte adhesion molecule-1 (E-selectin) on endothelial cells correlates with the degree of mononuclear cell infiltration in the early inflammatory lesion of SSc [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subpopulations of lymphocytes from patients with SSc, namely activated/cytotoxic/inducer T cells, natural killer (NK) cells, and some helper T cells, have a markedly increased ability to adhere to endothelium [<a href="#rid42">42</a>]. The number of highly adherent cells appears to be diminished in the peripheral blood of patients with SSc, as suggested by an overall reduction in adhesion of peripheral mononuclear cells to endothelium in an in vitro assay. It was postulated that this subpopulation of lymphocytes was eliminated from the circulation through enhanced in vivo adhesion aided by chemotactic forces and by a highly permeable endothelium.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mononuclear cells from patients with SSc which migrate into the extracellular matrix express differentiation markers of activated T cells including CD3, CD4, CD45, human leukocyte antigen (HLA)-DR, and lymphocyte function associated antigen-1 (LFA-1) [<a href="#rid43">43</a>]. These cells also have subsets of integrin molecules on their surface, including those of the beta 1 and beta 2 class, that facilitate binding to other cells including fibroblasts and tissue components such as type I and IV collagens, fibronectin, and laminin [<a href="#rid44">44,45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The peripheral blood of patients with SSc disorders contains a higher proportion of such activated CD3 and CD4 double-positive cells that migrate in vitro into an endothelial cell-covered collagen matrix than do healthy controls (71 versus 56 percent) [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is growing appreciation that the innate immune system is likely to be involved in pathogenesis of SSc. Genetic and functional studies have provided evidence for infiltration of cells of the monocyte or macrophage lineages in the skin and lung of patients with SSc, as well as evidence of altered expression and function of toll-like receptors [<a href="#rid47">47,48</a>]. Different subpopulations of macrophages may be critical to different stages and sites of disease [<a href="#rid49">49</a>].</p><p></p><p>Further inflammatory agents including histamines, kinins, complement, antibodies, free radicals, thromboxanes, leukotrienes, oxidized low-density lipoproteins (LDLs), and cytolytic T cells are all possible additional mediators of the deranged immunologic processes present in SSc.</p><p class="headingAnchor" id="H11"><span class="h2">Autoantibodies</span><span class="headingEndMark"> — </span>Approximately 95 percent of patients with SSc have circulating autoantibodies directed against one or more of a number of antigens. These include topoisomerase I (formerly called Scl-70) (20 to 45 percent) [<a href="#rid50">50</a>], centromere antigens (12 to 44 percent) [<a href="#rid50">50</a>], fibrillarin, ribonucleic acid (RNA) polymerase, PM-Scl, and fibrillin-1 [<a href="#rid51">51</a>], as well as RNA I, II, and III (20 percent) (<a class="graphic graphic_table graphicRef59732" href="/z/d/graphic/59732.html" rel="external">table 1</a>) [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Laboratory testing'</a>.)</p><p>Although not very sensitive, antitopoisomerase-I (Scl-70) antibodies are highly specific for SSc (98 to 100 percent) and correlate with a higher risk of interstitial lung disease [<a href="#rid1">1</a>]. Higher concentrations or titers are also associated with more extensive skin involvement and with higher disease activity [<a href="#rid53">53</a>]. Anticentromere antibodies (ACA) are associated with limited cutaneous involvement.</p><p>The inciting stimulus for the production of these autoantibodies is unknown. One possibility is that the targets for these autoantibodies are autoantigens that have been fragmented via reactive oxygen species and specific metals, such as copper or iron [<a href="#rid54">54</a>]. Immunogenic peptides are subsequently formed which are capable of breaking tolerance, inducing antibodies, and, through epitope spreading, developing antibodies to other epitopes. In addition, the involvement of metals provided a rationale for the use of <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a>, a metal chelator, in the treatment of SSc. </p><p>It is also possible that, in patients with cancer-associated SSc, tumors may induce these autoantibodies by producing somatic mutations, which then induce antibody formation against the mutated protein. As an example, somatic mutations in the POL3RA gene, which encodes RNA polymerase III, may induce anti-RNA polymerase III autoantibodies that may be involved in development of SSc. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Laboratory testing'</a>.)</p><p>Another possibility is that these antibodies arise in response to an infection and, via molecular mimicry, crossreact with a native antigen. In one report, for example, antibodies directed against cytomegalovirus and found in patients with SSc-induced apoptosis in endothelial cells via an interaction with a cell surface protein complex [<a href="#rid55">55</a>].</p><p>Immunoglobulin G (IgG) antibodies generally mirror T-cell response to antigen, and most workers believe it is the T cells which will be pathogenic. However, antibodies can, under different circumstances, be directly pathogenic (as described above), can be additive to T-cell damage, or can block T cells [<a href="#rid1">1</a>].</p><p>Autoantibodies that interact with fibroblasts could potentially play a pathogenic role in SSc. One study of sera from 69 patients with diffuse and limited SSc, 30 patients with sarcoidosis, and 50 healthy controls found elevated levels of antifibroblast antibodies of IgG-class in 58 percent and IgM-class in 33 percent of those with SSc, but found the same in only 1 of 30 patients with sarcoidosis (3 percent) and in none of the healthy controls [<a href="#rid56">56</a>]. Sera-containing antifibroblast antibodies promoted increased expression of the intercellular adhesion molecule-1 (ICAM-1) on cultured human fibroblasts and increased both messenger RNA (mRNA) and secretion of a number of proinflammatory cytokines.</p><p>The autoantibodies discussed above are not necessarily mutually exclusive. Indeed, a strong correlation was noted in one study between the intensity of antifibroblast staining with immunoglobulins from patients with SSc and reactivity of Scl-70 antibodies [<a href="#rid57">57</a>]. Further investigation demonstrated that affinity-purified antitopoisomerase antibodies were able to bind to the cell surface of cultured fibroblasts. Some data suggest that topoisomerase I on the fibroblast surface mediates antifibroblast activity [<a href="#rid58">58</a>].</p><p>The presence of antibodies to receptors for platelet-derived growth factor (PGDF) in the serum of patients with SSc may be a relatively specific finding, and profibrotic effects of agonistic antibody binding to the fibroblast PGDF receptor suggest a potentially pathophysiological role for such antibodies. This was illustrated in a study of 46 patients with SSc, 75 controls, and 10 patients who underwent allogeneic bone marrow transplants and who developed graft-versus-host disease (GVHD) with skin involvement [<a href="#rid59">59</a>]. A biologic assay that assessed the stimulatory effect of immunoglobulin G (IgG) was increased (&gt;99 percentile for healthy persons) in all of those with SSc but in none of those with systemic lupus erythematosus, rheumatoid arthritis, primary Raynaud phenomenon, or interstitial lung disease. The stimulatory activity was present in Ig obtained from the 10 patients with GVHD [<a href="#rid60">60</a>].</p><p>Other studies have demonstrated presence of agonist antibodies to vascular receptors for endothelin (ET) and angiotensin was associated with poor long-term survival, although the contribution to pathogenesis remains unclear [<a href="#rid61">61</a>]. However, a report demonstrated antibodies against G protein coupled receptors in a number of diseases including SSc and suggested that these may provide a key link between pathobiology in target cells and the adaptive immune system [<a href="#rid62">62</a>].</p><p>Other autoantibodies that have been observed include antinucleolar, anti-Th/To, anti-Ku, antiphospholipid, anti-Sm, anti-RNP, anti-Ro, antineutrophil cytoplasmic antibody (ANCA), anti-U1 RNA, antinucleosome, anti-fibrillin-1 (FBN1), anti-matrix metalloproteinases 1 and 3, and anti-endothelial cell specificities [<a href="#rid25">25,63-66</a>].</p><p>It is becoming apparent that the clinical diversity seen between the key antinuclear antibody (ANA) subgroups in SSc are associated with relevant differences in gene and protein expression. This may also be relevant in determining potential differential response to targeted therapies such as <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> that have been observed in clinical trials [<a href="#rid67">67,68</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Graft-versus-host disease or microchimerism</span><span class="headingEndMark"> — </span>Some investigators have postulated that SSc is a variant of GVHD, since both disorders share clinical features such as prominent involvement of the skin, lung, and esophagus. An animal model of GVHD replicates many of the features of human disease [<a href="#rid69">69,70</a>]. Indirect support for this hypothesis is provided both by an increased frequency of persistent fetal cells among women with SSc and a history of pregnancy (as compared with normal women with a history of pregnancy) and by the presence of fetal cells in the involved skin of such patients [<a href="#rid71">71-74</a>]. Cells derived from the fetus may also be found in other tissues of women with SSc, most often in the spleen [<a href="#rid75">75</a>]. These associations, however, do not prove causality [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H13"><span class="h1">GROWTH FACTORS AND CYTOKINES</span><span class="headingEndMark"> — </span>The cell-cell and cell-matrix interactions mentioned above may stimulate the production and release of growth factors and cytokines able to mediate the proliferation and activation of vascular and connective tissue cells, particularly fibroblasts. The importance of cytokines in the pathogenesis of systemic sclerosis (SSc) has been strengthened by the realization that the endothelial cell and the fibroblast are both capable of producing factors essential for the development of this illness (<a class="graphic graphic_table graphicRef62238" href="/z/d/graphic/62238.html" rel="external">table 2</a>).</p><p>It had been previously assumed that the major sources of paracrine factors in SSc were inflammatory cells and lymphocytes. However, fibroblasts and endothelial cells can also produce and release cytokines, and they can mobilize growth factors, such as basic fibroblast growth factor, from the extracellular matrix [<a href="#rid77">77</a>]. These observations raise the possibility of reciprocal interactions between all of these cell types, which may be central to disease pathogenesis.</p><p>Autocrine or paracrine loops of cytokines may also be responsible for the generation and/or persistence of the SSc phenotype seen after several cell passages in conventional tissue culture [<a href="#rid78">78,79</a>]. A number of possible interactions involving various mediators and several cell types may occur (<a class="graphic graphic_figure graphicRef67862" href="/z/d/graphic/67862.html" rel="external">figure 2</a>). Different loops may also operate within clinical subsets and may be variously expressed at different stages of the disease.</p><p class="headingAnchor" id="H14"><span class="h2">Potential pathogenic cytokines</span><span class="headingEndMark"> — </span>Large numbers of cytokines have been examined as potential effectors of fibrosis in SSc (<a class="graphic graphic_table graphicRef66277" href="/z/d/graphic/66277.html" rel="external">table 3</a>). Included in this group are:</p><p class="bulletIndent1"><span class="glyph">●</span>Transforming growth factor-beta (TGF-beta)</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet-derived growth factor (PDGF)</p><p class="bulletIndent1"><span class="glyph">●</span>Interleukin (IL) 1, IL-4, IL-6, IL-8, IL-13, and IL-17</p><p class="bulletIndent1"><span class="glyph">●</span>Connective tissue growth factor</p><p class="bulletIndent1"><span class="glyph">●</span>Insulin-like growth factors (IGF)</p><p class="bulletIndent1"><span class="glyph">●</span>Basic fibroblast growth factor (bFGF)</p><p class="bulletIndent1"><span class="glyph">●</span>Interferon-gamma (IFN-gamma)</p><p class="bulletIndent1"><span class="glyph">●</span>CXCL4</p><p class="bulletIndent1"><span class="glyph">●</span>Monocyte chemotactic protein-1 and -3</p><p class="bulletIndent1"><span class="glyph">●</span>Tumor necrosis factor (TNF)</p><p></p><p>It is highly unlikely that any one mediator can account for the pathogenesis of SSc, since cytokines are produced by several cell types that may interact through autocrine and paracrine pathways. The following sections address the biological properties of those growth factors and cytokines felt to be most likely to contribute to the development of SSc. </p><p class="headingAnchor" id="H15"><span class="h2">Effects on cell-cell interactions</span><span class="headingEndMark"> — </span>Cytokines can modulate cell-cell interactions in addition to the direct cellular effects previously mentioned. As an example, IL-1 and TNF-alpha both enhance leukocyte adhesions to endothelial cells, their subsequent extravasation into the extracellular matrix, and the number of activated endothelial cells in SSc lesions.</p><p class="headingAnchor" id="H16"><span class="h2">Effects on adhesion molecules</span><span class="headingEndMark"> — </span>Cytokines may directly upregulate key adhesion molecules, including intracellular adhesion molecule (ICAM)-1. As an example, fibroblasts from patients with SSc bind to lymphocytes in vitro, through interactions between ICAM-1 and lymphocyte function-associated antigen (LFA)-1 [<a href="#rid80">80</a>]. In addition, IL-1, TNF, and IFN-gamma have been shown to modulate the expression of ICAM-1 by SSc fibroblasts, an effect enhanced by the female sex hormone B-estradiol. This may be an important observation in view of the female predominance of this disease [<a href="#rid81">81</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Effects on the SSc fibroblast phenotype</span><span class="headingEndMark"> — </span>Many studies have focused on the possible paracrine factors that may initiate or maintain the typical SSc fibroblast phenotype. Early investigations demonstrated the inherent ability of SSc cells to grow in low serum environments and their reduced responsiveness to exogenous PDGF. These findings were explained by the observation that SSc fibroblasts secrete PDGF, thereby rendering them less sensitive to exogenous growth factors [<a href="#rid82">82</a>]. Subsequent work has shown that there is considerable enhancement of the fibroblasts’ mitogenic response to other mediators, including TGF-beta, IL-6, and endothelin (ET)-1.</p><p class="headingAnchor" id="H18"><span class="h2">Transforming growth factor-beta</span><span class="headingEndMark"> — </span>The marked matrix stimulatory properties of the transforming growth factors, particularly TGF-beta, have implicated these proteins as potentially important mediators in SSc. However, studies of skin biopsies, bronchoalveolar lavage (BAL), and blood samples from patients with SSc have produced conflicting results on the levels of TGF-beta messenger ribonucleic acid (mRNA) and protein, despite the fact that TGF-beta can be readily demonstrated in both involved skin and the fibrotic lung [<a href="#rid83">83-85</a>]. These unexpected results may be explained by the different clinical characteristics of the SSc patients enrolled in the two studies. These patients may have been representative of unique SSc subsets, may have been studied at different stages of their disease process, or may have had variable rates of disease progression. These variables make exact comparison of results from different studies exceedingly difficult.</p><p>Even if TGF-beta is an important mediator in the pathogenesis of SSc, it is likely to operate in concert with other cytokines. Moreover, different downstream-signaling pathways may be invoked for short- or long-term (chronic) TGF-beta-mediated effects. A central role for the Smad family of proteins is postulated. Smads are evolutionarily conserved proteins that mediate transcriptional activation by members of the TGF-beta superfamily of cytokines. Some (eg, Smad3) activate intracellular signaling, whereas others (eg, Smad7) are inhibitory.</p><p>The role of TGF-beta in the acquisition and maintenance of the SSc phenotype is also unclear. Attempts to induce long-term enhancement of collagen-1 production by fibroblasts via regular pulsed exposure to TGF-beta have failed, as have attempts to demonstrate coordinated regulation of collagen-1 and TGF-beta by SSc fibroblasts [<a href="#rid86">86-88</a>]. Furthermore, collagen and TGF-beta type II receptor mRNA appear to be inducible by TGF-beta in both SSc cells and control cells, indicating that the lack of a sustained elevation in collagen synthesis is not due to lack of responsiveness by the fibroblasts; it may, however, reflect the transient nature of TGF-beta-induced fibrogenesis [<a href="#rid89">89</a>].</p><p>The following evidence suggests that TGF-beta may indirectly influence other cytokines, primarily PDGF, to promote fibrogenesis:</p><p class="bulletIndent1"><span class="glyph">●</span>TGF-beta is an indirect mitogen for fibroblasts, acting via interaction with the PDGF-alpha receptor and inducing expression of other mitogenic growth factors including connective tissue growth factor (CTGF, also termed CCN-2).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibroblasts from patients with SSc, in contrast to normal adult newborn foreskin fibroblasts, respond to TGF-beta-1 by expressing greater numbers of PDGF-alpha receptors on their surface, increasing PDGF-alpha receptor protein, and elevating mRNA levels [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TGF-beta increases the mitogenic responses to platelet-derived growth factor (PDGF)-AA. PDGF-AA binds only to the PDGF-alpha receptor, in contrast to PDGF-beta, which binds to both the alpha and beta receptors of SSc cells. PDGF-AA has been found immunohistochemically in SSc dermis near blood vessels and hair follicles but not in normal skin.</p><p></p><p class="headingAnchor" id="H19"><span class="h3">Transforming growth factor-beta receptors</span><span class="headingEndMark"> — </span>The possibility that receptors for TGF-beta on fibroblasts have a role in SSc pathogenesis has also been explored. Expression of type I and type II TGF-beta receptors were increased more than twofold in fibroblasts cultivated from the skin of patients with diffuse SSc when compared with control fibroblasts [<a href="#rid91">91</a>]. Production of collagen mRNA by cultivated fibroblasts could be decreased by anti-TGF-beta antibodies and by transfection with TGF-beta receptor antisense oligonucleotides.</p><p>Upregulation of type I and type II TGF-beta receptors also occurs in fibroblasts obtained from lesional skin of patients with localized forms of SSc, such as morphea and linear SSc [<a href="#rid92">92</a>]. The stimulus and mechanism for the increased expression of these receptors are unknown.</p><p>Decreased turnover of TGF-beta receptors and a failure of control over receptor signaling could also result in an increased sensitivity to TGF effects. This mechanism was suggested by the finding, in cultured skin fibroblasts of patients with diffuse cutaneous SSc, of impaired ubiquitin-mediated degradation of TGF-beta receptors; and by an absence of negative feedback via inhibitory molecules (Smad7) [<a href="#rid93">93</a>]. Defective induction of Smad7 signaling may also contribute to altered TGF-beta responsiveness in SSc [<a href="#rid94">94</a>].</p><p>Increased expression of endoglin, a non-activating TGF-beta receptor, as indicated by modest elevation in fibroblast endoglin mRNA and membrane-bound protein, occurs in sclerodermatous skin, and there is preliminary evidence that these levels increase with the duration of disease. [<a href="#rid95">95</a>]. It is unclear what role, if any, endoglin may play in SSc. Endoglin is important in angiogenesis, and mutations in the endoglin gene are responsible for some forms of hereditary hemorrhagic telangiectasia. (See  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)", section on 'Pathophysiology'</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Platelet-derived growth factor</span><span class="headingEndMark"> — </span>These results suggest that TGF-beta may increase the expression of fibroblast populations in SSc by activating the PDGF-AA ligand or PDGF-alpha receptor pathway. PDGF, in turn, has been shown to increase the rate of transcription of bFGF in normal fibroblasts. Both PDGF and bFGF are deposited around blood vessels in the lower dermis of early lesions, suggesting that these growth factors may be related to endothelial injury in SSc.</p><p>PDGF also regulates the expression of genes that are important in the mitogenic response. As an example, an increase in ras oncogene product in early lesional skin was noted in association with vascular endothelium and mononuclear cells [<a href="#rid96">96</a>]. Other studies have established that fibroblasts expressing the ras oncogene produce more bFGF, suggesting that bFGF may also play an autocrine role leading to growth stimulation.</p><p class="headingAnchor" id="H21"><span class="h2">Connective tissue growth factor</span><span class="headingEndMark"> — </span>There is growing evidence for upregulation of the TGF-beta-induced matricellular protein known as CTGF in various forms of fibrosis [<a href="#rid97">97</a>]. Increased production by SSc fibroblasts has been consistently found. Mean plasma levels of an N-terminal fragment of CTGF are markedly elevated in patients with diffuse skin involvement and are moderately increased in those with limited cutaneous disease when compared with healthy controls [<a href="#rid98">98</a>].</p><p>Initially, it was suggested that CTGF may be important in sustaining a profibrotic fibroblast phenotype as a secondary cytokine induced by TGF-beta. However, a body of evidence suggests a more complex activity as a matricellular protein exerting some direct effects on fibroblasts by regulating activity or bioavailability of TGF-beta [<a href="#rid99">99</a>] or effects on cell adhesion and fibroblast-matrix interaction [<a href="#rid100">100</a>].</p><p class="headingAnchor" id="H116029977"><span class="h2">Interleukin 6 and related cytokines</span><span class="headingEndMark"> — </span>There has been an increased focus on IL-6 as a mediator in SSc based upon the promising early clinical data for use of anti-IL-6 antibody in diffuse SSc [<a href="#rid101">101</a>] and emerging clinical data suggesting that higher levels of serum IL-6 may associated with more severe skin disease [<a href="#rid102">102</a>] or greater progression of lung fibrosis [<a href="#rid103">103</a>]. SSc cells appear to produce much more IL-6 than controls [<a href="#rid104">104</a>], and IL-6 may represent one of the soluble mitogenic factors transferable in culture medium derived from such cells [<a href="#rid105">105</a>]. The role of IL-6 is unclear, but it may modulate activity of other key profibrotic pathways in fibroblasts as well as its effect on immune cells. This may be especially relevant to the immune system, favoring Th17 differentiation or macrophage M2 polarization. Interestingly, attenuation of a fibrogenic M2 macrophage gene expression signature in skin was associated with possible clinical response to blocking IL-6 in a clinical trial [<a href="#rid101">101</a>], and studies of explant skin fibroblasts have shown remarkable attenuation of molecular activation following therapeutic administration of an anti-IL-6 receptor blocking antibody [<a href="#rid106">106</a>]. Other members of the IL-6 family have also been suggested as possible mediators in SSc pathogenesis, including IL-31, oncostatin M, and IL-11 [<a href="#rid107">107</a>].</p><p class="headingAnchor" id="H22"><span class="h2">Interleukin 1</span><span class="headingEndMark"> — </span>Interest has also been directed to the production and regulation of the cytokines IL-1 by SSc fibroblasts. IL-1a is also produced excessively by SSc fibroblast and may contribute, via autocrine or paracrine pathways, to their abnormal properties in culture [<a href="#rid108">108,109</a>]. Some evidence suggests that keratinocyte-derived IL-1a is important in regulating fibroblast properties in SSc [<a href="#rid110">110</a>].</p><p class="headingAnchor" id="H23"><span class="h2">Interleukin 4</span><span class="headingEndMark"> — </span>IL-4 may have a profibrotic effect on scleroderma dermal fibroblasts. These cells have IL-4 receptors, and, when cultured in IL-4 containing media, the production of collagen is significantly increased [<a href="#rid111">111</a>]. IL-4 shares biologic properties and receptor specificity with the related cytokine IL-13. Clinical trial results suggest that blocking IL-4 and IL-13 may benefit SSc skin fibrosis [<a href="#rid112">112</a>]. These findings may reflect the role of these cytokines in alternative macrophage activation and the M2 profibrotic phenotype [<a href="#rid112">112</a>].</p><p class="headingAnchor" id="H24"><span class="h2">Chemokines</span><span class="headingEndMark"> — </span>A number of chemokines have been reported to be elevated in the serum and biopsies of SSc skin. CXCL4, also known as platelet-activating factor 4, belongs to the CXC family of chemokines. CXCL4 is a protein that is a potent antiangiogenic chemokine that influences angiogenesis through an integrin-dependent mechanism [<a href="#rid113">113</a>]. It also inhibits the expression of the antifibrotic cytokine IFN-gamma, and upregulates profibrotic cytokines IL-4 and IL-13 [<a href="#rid114">114</a>].</p><p>Further, CXCL4 has been implicated in the pathogenesis of SSc based on findings that plasma levels are elevated in patients with SSc, and high plasma levels correlate with progression of both skin and pulmonary fibrosis, as well as pulmonary arterial hypertension [<a href="#rid115">115</a>]. This was demonstrated in a proteome-wide analysis in which CXCL4 levels were measured in patients with SSc and compared with controls, including patients with rheumatoid arthritis, ankylosing spondylitis, and systemic lupus erythematosus. CXCL4 was the predominant protein secreted by plasmacytoid dendritic cells in patients with SSc, both in the circulation and the skin. CXCL4 was also the only chemokine that correlated with faster progression of skin and lung fibrosis. Although interesting, these observations require further confirmation to assess whether targeting this pathway may be helpful in managing the disorder.</p><p>The role of plasmacytoid dendritic cells has been an area of interest in the pathogenesis of SSc as they are the major source of type I interferon, which has been implicated in the pathogenesis of several autoimmune diseases [<a href="#rid116">116-119</a>]. However, this may suggest that altered function of these cells is a generic feature of autoimmunity, and further studies are needed to delineate scleroderma-specific importance.</p><p>It has been suggested that CC motif chemokine receptor 2 (CCR2) overexpression of monocyte chemotactic protein (MCP)-1 (CC motif ligand 2 [CCL2]) associates with early-stage disease and may promote fibrosis [<a href="#rid120">120</a>]. Interactions with other cytokines including IL-4 have also been demonstrated [<a href="#rid111">111</a>].</p><p>mRNA for MCP-3, a member of the CC chemokine family, is overexpressed by dermal fibroblasts cultured from tight-skin mice, a model of SSc [<a href="#rid121">121</a>]. Immunostaining for this protein in the skin of patients and healthy controls demonstrated more MCP-3 in the lesional skin of those with early onset diffuse disease than in those with limited cutaneous involvement or in healthy controls. This chemokine could contribute to fibrosis through effects on extracellular matrix production as a chemoattractant for leukocytes. Chemokine expression in lung tissue may be relevant to the recruitment of fibroblast precursor cells and to the development of lung fibrosis in SSc [<a href="#rid122">122-124</a>].</p><p>The chemokine CCL18 has also been shown to predict progression of lung fibrosis [<a href="#rid125">125</a>] and is a potential marker of M2 macrophage polarization that is attenuated in serum by IL-6 receptor blockade [<a href="#rid101">101</a>].</p><p class="headingAnchor" id="H2434471446"><span class="h2">Lipid mediators</span><span class="headingEndMark"> — </span>There is emerging evidence for the importance of profibrotic lipid mediators in SSc pathogenesis. In particular, the lysophosphatidic acid (LPA) pathway appears to be important based upon preclinical studies and proof-of-concept trials. LPA1 synthesized from arachidonic acid by autotoxin promotes fibrotic pathways including stimulation of IL-6 production. This is supported by clinical trials showing downregulation of profibrotic genes in skin by an LPA1 receptor antagonist associated with potential clinical benefit in skin fibrosis [<a href="#rid126">126</a>].</p><p class="headingAnchor" id="H25"><span class="h2">Summary of the effects of growth factors and cytokines</span><span class="headingEndMark"> — </span>It seems likely that the interplay between a number of cytokines and growth factors will be found to underlie the pathogenesis of SSc. Increased levels of circulating IL-1, IL-2, IL-2R, IL-4, IL-8, IL-17, TNF-alpha, interferon, and antibodies to IL-6 and IL-8 have been found in patients with SSc [<a href="#rid127">127-130</a>]. However, the presence of high levels of a particular cytokine does not necessarily imply a causative role. In addition, it has become clear that the interpretation of these studies is dependent upon the assay used (bioassay or immunoassay) and upon a realization that many factors interfere with each system. Despite these reservations, it may be inferred that the increased levels of the various cytokines support a cellular immune mechanism in SSc and an ongoing expansion of T cells and of their secreted products.</p><p>It is important to remember that, because cytokines influence each other, the pattern of total cytokine production may be more important than any individual cytokine. The soluble cytokines are not exclusive to SSc, being found in many other diseases. However, their presence, pattern of expression, and known interactions may provide clues to the correct cell-type and to relevant tissues involved in disease development and may aid in the development of directed therapy.</p><p class="headingAnchor" id="H26"><span class="h1">FIBROBLAST ACTIVITY AND COLLAGEN SYNTHESIS</span><span class="headingEndMark"> — </span>The development of the fibroblast capable of excess matrix production and deposition is the hallmark of systemic sclerosis (SSc) (<a class="graphic graphic_table graphicRef56639" href="/z/d/graphic/56639.html" rel="external">table 4</a>). Fibroblast cultures from both the papillary and the reticular dermis of patients with SSc have been found to produce increased amounts of collagen and other extracellular matrix components; this has been demonstrated in vivo, in biopsy specimens, and in vitro in fibroblast cultures derived from lesional SSc skin. These abnormalities persist through many passages in tissue culture. Normal dermal fibroblasts, in contrast, are relatively quiescent, showing little tendency to proliferate or to elaborate extracellular matrix in the absence of positive stimuli.</p><p>Abnormal fibroblast activity in SSc can also be identified in organs other than skin. As an example, increased collagen synthesis by fibroblasts isolated from lung biopsy specimens of patients with SSc lung disease has been demonstrated, thereby suggesting a similar pathogenic mechanism in lung and skin [<a href="#rid131">131</a>].</p><p>Increased collagen production is not a feature of all SSc skin fibroblast strains or of all fibroblasts within a culture population; it may, therefore, be limited to discrete subpopulations [<a href="#rid132">132</a>]. Indeed, differences between normal and SSc populations are often more apparent when individual subpopulations are studied rather than mass populations. In situ hybridization studies have demonstrated that high collagen-producing subpopulations of fibroblasts are frequently observed in close proximity to mononuclear cells and adjacent to blood vessels in patients with SSc [<a href="#rid133">133,134</a>].</p><p class="headingAnchor" id="H27"><span class="h2">Activating and inhibitory signals</span><span class="headingEndMark"> — </span>Increased matrix production by fibroblasts may result from a net excess of positive activating signals and/or from a reduction in inhibitory signals. Positive paracrine mediators may be derived from immune cells, from endothelial cells, or from the fibroblasts themselves. In turn, inhibitory influences may arise from interactions with noncellular extracellular matrix components such as collagen fibers and fibronectin. Such interactions appear to be potent down-regulators of collagen synthesis by normal dermal fibroblasts and also modulate cell morphology, proliferative capacity, and cytokine responsiveness. It has been suggested that down-regulation of nuclear hormone receptors, including peroxisome proliferator-activated receptor gamma [<a href="#rid135">135</a>] and others, may provide a mechanism by which there is a failure of appropriate feedback inhibitory signals in activated fibroblasts in SSc [<a href="#rid136">136</a>]. Despite promising preclinical data, a clinical trial did not suggest benefit in SSc from a peroxisome proliferator-activated receptor (PPAR) agonist, suggesting this may not be a critical primary defect in SSc [<a href="#rid137">137</a>].</p><p class="headingAnchor" id="H28"><span class="h2">The SSc fibroblast</span><span class="headingEndMark"> — </span>One potential mechanism for the development of the activated fibroblast places the initiating event in the vascular bed, leading to growth factor and cytokine production with resulting fibroblast activation and with subsequent fibrosis. Other studies have added complexity by demonstrating that fibroblasts involved in tissue repair may be derived from diverse origins, including bone marrow-derived progenitor cells, local epithelial cells, or resident progenitor or stem cell populations; however, a unifying mechanism may be the dependence of these cell types on transforming growth factor-beta (TGF-beta) and its regulated pathways and mediators [<a href="#rid138">138</a>]. Thus, deletion of TGF-beta responses by genetic modification in animal models appears to attenuate fibrosis and scar formation [<a href="#rid139">139,140</a>]. This may have implications for novel treatment strategies [<a href="#rid141">141</a>]. While this unifies several of the different pathogenic events seen in SSc, it cannot completely explain the abnormal phenotype of the SSc fibroblast as indicated by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Although dermal mononuclear cell infiltrates are common in vivo, they are not universal, and in the later stages of the disease there is ongoing dermal fibrosis in the absence of apparent immune cell activity. Furthermore, SSc fibroblasts in vitro are often less dependent upon serum supplementation and other growth promoting factors than normal, healthy fibroblast cultures [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, the collagen-secreting ability of SSc fibroblasts continued at the same rate whatever their feeding conditions, unlike control fibroblasts which increased their collagen output briskly in response to frequent serum replenishment [<a href="#rid142">142</a>].</p><p></p><p>It therefore appears that immune cell or other influences may lead to the development of a relatively autonomous activated fibroblast strain. Several of the following possibilities may explain such behavior:</p><p class="bulletIndent1"><span class="glyph">●</span>Soluble fibroblast products, which maintain the SSc phenotype, may have been induced, allowing an autocrine feedback loop to become established. However, no such mechanism has been conclusively shown, although several cytokines have been considered, particularly interleukin (IL) 1, IL-6, platelet-derived growth factor (PDGF), and TGF-beta.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second possibility is the induction of a permanent dysfunction of some intracellular regulatory gene(s), such as a proto-oncogene or its product, which then acts to increase matrix synthesis. As an example, cultured fibroblasts from patients with SSc have more immunoreactive protein kinase C-delta (PKC-delta) than those of healthy controls; increased transcription of type I collagen genes in cells derived from these patients can be abrogated in vitro by a selective inhibitor of PKC-delta, rottlerin [<a href="#rid143">143</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A third potential mechanism is an immune cell-mediated selection of a subpopulation of fibroblasts already committed to high levels of collagen production or preferential proliferation. The clonal expansion of such fibroblast subsets under immune, hypoxic, or other influences may perpetuate the fibrotic processes in vivo as well as the experimental situation in vitro.</p><p></p><p class="bulletIndent1">The metabolic heterogeneity of fibroblasts is well-established, and analysis of fibroblast clonal populations shows marked heterogeneity of cell surface markers, proliferation, collagen production, collagenase synthesis, and prostaglandin E2 biosynthetic responses to IL-2 or other mediators [<a href="#rid132">132</a>]. Several studies on clonal selection in SSc fibroblasts have been performed with varying results.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A fourth possibility is that the interaction of fibroblasts with the extracellular matrix alters cellular function, including the control of matrix deposition and the response to cytokines. The question has been raised as to whether SSc fibroblasts may differ in their adhesion to matrix. In general, interactions of cells with matrix proteins involve specific cell membrane proteins that belong to different families of receptors such as integrins, cell surface proteoglycans, and anchorins. This is a very complex process involving different domains (eg, RGD [arginine-glycine-aspartate] sequences) and various receptor molecules which then mediate different cellular signals that are transmitted to the nucleus. It has been suggested that stiffness of extracellular matrix may be important in generation or persistence of myofibroblasts phenotype. This is based on observations that suggest that mechanical stiffness of fibrotic skin or lung may promote further fibroblast activation or myofibroblasts persistence [<a href="#rid144">144</a>]. It has been suggested that altered matrix proteins may also contribute to innate immune activation relevant to persistent fibrosis [<a href="#rid145">145</a>].</p><p></p><p class="bulletIndent1">Microfibrils of fibrillin-1 produced by fibroblasts from uninvolved skin of patients with SSc may be less stable than fibrils produced by similar cells of those without disease [<a href="#rid146">146</a>]. The mechanism for the observed instability is uncertain. Findings that suggest that the fibrillar instability may be pathogenic include the association between SSc and genetic markers near the fibrillin-1 gene among Choctaw Indians [<a href="#rid147">147</a>], as well as a tandem repeat in the fibrillin gene of the tight skin mouse [<a href="#rid148">148</a>]. (See  <a class="medical medical_review" href="/z/d/html/7557.html" rel="external">"Risk factors for and possible causes of systemic sclerosis (scleroderma)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A fifth possibility, for which there is some support, is that a stable epigenetic change leads to a profibrotic phenotype of the fibroblast. Hypermethylation of deoxyribonucleic acid (DNA) and deacetylation of histone proteins, changes that decrease the transcriptional activity in the region of a promoter of a gene (FLI1 gene), have been noted in cultured fibroblasts from patients, and hypermethylation of the promoter was present in samples of skin from patients but not in three control cell lines [<a href="#rid149">149</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As in other complex diseases, new insights are emerging from studies using high-dimensional integrated analysis of proteomics and transcriptomics from skin and blood. These approaches are providing powerful insight into disease pathobiology and also identifying potential molecular markers of key pathogenic mechanisms [<a href="#rid150">150</a>]. Single cell approaches are proving especially powerful in defining potentially important fibroblast subpopulations and elucidating critical regulators and pathways that may be targeted therapeutically [<a href="#rid151">151,152</a>].</p><p></p><p class="headingAnchor" id="H29"><span class="h2">Models of extracellular matrix</span><span class="headingEndMark"> — </span>Another area of investigation uses models to simulate the extracellular milieu seen by SSc fibroblasts. The extracellular matrix may be simulated by the use of three-dimensional collagen gels. When normal fibroblasts are seeded in such gels, they contract the gels, change their morphology, and modulate several of their specific functions, including protein synthesis and a marked reduction in collagen-specific mRNA levels. When SSc cells are seeded in a similar fashion, they contract the gel but do not downregulate collagen synthesis compared with normal cells.</p><p>This impairment in downregulation may reflect one of the following [<a href="#rid153">153</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Changes in the a1b1 integrin expression on the fibroblast cell surface</p><p class="bulletIndent1"><span class="glyph">●</span>Altered intracellular signaling secondary to integrin-ligand binding</p><p class="bulletIndent1"><span class="glyph">●</span>Altered regulation of collagen gene transcription in these cells</p><p></p><p>It has also been suggested that altered stability of the collagen mRNA transcript may be involved in determining steady-state mRNA levels in three-dimensional collagen gel versus monolayer fibroblast cultures [<a href="#rid154">154</a>].</p><p>Other relevant areas of investigation include studies of the complex regulation of extracellular matrix degradation. Early reports suggested that matrix degradative processes were not altered in SSc; however, several studies suggest that this may not be the case [<a href="#rid155">155,156</a>]. As an example, one product of matrix degradation, endostatin (a fragment of type XVIII collagen and an inhibitor of angiogenesis), was increased significantly in patients with SS compared with healthy controls (53.2 versus 9.9 ng/mL) [<a href="#rid157">157</a>].</p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>The pathogenesis of systemic sclerosis (SSc) is better defined at a molecular level and involves multiple cell types from the innate or adaptive immune system, vasculature, and connective tissue.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibrogenic fibroblasts ultimately mediate the fibrotic pathology of SSc, but the factors determining inappropriate activation and the relative importance of enhanced activating influences or reduced down-regulatory signals are not well understood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment for almost all aspects of SSc remains inadequate. Elucidation of the precise interplay between the immunologic, vascular, and fibrotic components of SSc is likely to be an important first step toward more effective therapy. As key growth factors or chemokines are identified, there may be new opportunities for a more targeted approach to therapy. The ultimate goal of targeted subset and stage-specific therapy will depend upon progress in the understanding of the complex pathogenesis of this disease.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Black CM. The aetiopathogenesis of systemic sclerosis: thick skin--thin hypotheses. The Parkes Weber Lecture 1994. J R Coll Physicians Lond 1995; 29:119.</a></li><li><a class="nounderline abstract_t">Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy. Lancet 1996; 347:1453.</a></li><li><a class="nounderline abstract_t">Piela-Smith TH, Korn JH. Lymphocyte modulation of fibroblast function in systemic sclerosis. Clin Dermatol 1994; 12:369.</a></li><li><a class="nounderline abstract_t">Sollberg S, Mauch C, Eckes B, Krieg T. The fibroblast in systemic sclerosis. Clin Dermatol 1994; 12:379.</a></li><li><a class="nounderline abstract_t">Gorlova O, Martin JE, Rueda B, et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet 2011; 7:e1002178.</a></li><li><a class="nounderline abstract_t">Radstake TR, Gorlova O, Rueda B, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010; 42:426.</a></li><li><a class="nounderline abstract_t">Pearson JD. The endothelium: its role in scleroderma. Ann Rheum Dis 1991; 50 Suppl 4:866.</a></li><li><a class="nounderline abstract_t">Levin ER. Endothelins. N Engl J Med 1995; 333:356.</a></li><li><a class="nounderline abstract_t">Flavahan NA, Flavahan S, Liu Q, et al. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000; 43:1886.</a></li><li><a class="nounderline abstract_t">Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991; 34:978.</a></li><li><a class="nounderline abstract_t">Zamora MR, O'Brien RF, Rutherford RB, Weil JV. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 1990; 336:1144.</a></li><li><a class="nounderline abstract_t">Yamane K, Miyauchi T, Suzuki N, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992; 19:1566.</a></li><li><a class="nounderline abstract_t">Vancheeswaran R, Magoulas T, Efrat G, et al. Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? J Rheumatol 1994; 21:1838.</a></li><li><a class="nounderline abstract_t">Vancheeswaran R, Azam A, Black C, Dashwood MR. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994; 21:1268.</a></li><li><a class="nounderline abstract_t">Kahaleh MB, LeRoy EC. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 1999; 31:195.</a></li><li><a class="nounderline abstract_t">Rolla G, Colagrande P, Scappaticci E, et al. Exhaled nitric oxide in systemic sclerosis: relationships with lung involvement and pulmonary hypertension. J Rheumatol 2000; 27:1693.</a></li><li><a class="nounderline abstract_t">Andersen GN, Caidahl K, Kazzam E, et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 2000; 43:1085.</a></li><li><a class="nounderline abstract_t">Ibba-Manneschi L, Niissalo S, Milia AF, et al. Variations of neuronal nitric oxide synthase in systemic sclerosis skin. Arthritis Rheum 2006; 54:202.</a></li><li><a class="nounderline abstract_t">Blake DR, Winyard P, Scott DG, et al. Endothelial cell cytotoxicity in inflammatory vascular diseases--the possible role of oxidised lipoproteins. Ann Rheum Dis 1985; 44:176.</a></li><li><a class="nounderline abstract_t">Bruckdorfer KR, Hillary JB, Bunce T, et al. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 1995; 38:1060.</a></li><li><a class="nounderline abstract_t">Stein CM, Tanner SB, Awad JA, et al. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996; 39:1146.</a></li><li><a class="nounderline abstract_t">Ogawa F, Shimizu K, Muroi E, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology (Oxford) 2006; 45:815.</a></li><li><a class="nounderline abstract_t">Dooley A, Gao B, Bradley N, et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford) 2006; 45:676.</a></li><li><a class="nounderline abstract_t">Kuwana M, Okazaki Y, Yasuoka H, et al. Defective vasculogenesis in systemic sclerosis. Lancet 2004; 364:603.</a></li><li><a class="nounderline abstract_t">Carvalho D, Savage CO, Black CM, Pearson JD. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 1996; 97:111.</a></li><li><a class="nounderline abstract_t">Sgonc R, Gruschwitz MS, Boeck G, et al. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000; 43:2550.</a></li><li><a class="nounderline abstract_t">Worda M, Sgonc R, Dietrich H, et al. In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum 2003; 48:2605.</a></li><li><a class="nounderline abstract_t">Ahmed SS, Tan FK, Arnett FC, et al. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Arthritis Rheum 2006; 54:2250.</a></li><li><a class="nounderline abstract_t">Kahaleh MB, Fan PS. Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol 1997; 83:32.</a></li><li><a class="nounderline abstract_t">Mulligan-Kehoe MJ, Drinane MC, Mollmark J, et al. Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum 2007; 56:3448.</a></li><li><a class="nounderline abstract_t">Sprott H, Müller-Ladner U, Distler O, et al. Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma). J Rheumatol 2000; 27:402.</a></li><li><a class="nounderline abstract_t">Springer TA. Adhesion receptors of the immune system. Nature 1990; 346:425.</a></li><li><a class="nounderline abstract_t">Sato S. Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 1999; 11:503.</a></li><li><a class="nounderline abstract_t">Claman HN, Giorno RC, Seibold JR. Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin". Arthritis Rheum 1991; 34:1495.</a></li><li><a class="nounderline abstract_t">Sollberg S, Peltonen J, Uitto J, Jimenez SA. Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum 1992; 35:290.</a></li><li><a class="nounderline abstract_t">Gruschwitz M, von den Driesch P, Kellner I, et al. Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 1992; 27:169.</a></li><li><a class="nounderline abstract_t">Sfikakis PP, Tesar J, Baraf H, et al. Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Immunol Immunopathol 1993; 68:88.</a></li><li><a class="nounderline abstract_t">Carson CW, Beall LD, Hunder GG, et al. Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol 1993; 20:809.</a></li><li><a class="nounderline abstract_t">Stratton RJ, Coghlan JG, Pearson JD, et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM 1998; 91:561.</a></li><li><a class="nounderline abstract_t">Denton CP, Bickerstaff MC, Shiwen X, et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995; 34:1048.</a></li><li><a class="nounderline abstract_t">Tan FK, Zhou X, Mayes MD, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006; 45:694.</a></li><li><a class="nounderline abstract_t">Rudnicka L, Majewski S, Blaszczyk M, et al. Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1992; 35:771.</a></li><li><a class="nounderline abstract_t">Prescott RJ, Freemont AJ, Jones CJ, et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992; 166:255.</a></li><li><a class="nounderline abstract_t">Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69:11.</a></li><li><a class="nounderline abstract_t">Gullberg D, Tingström A, Thuresson AC, et al. Beta 1 integrin-mediated collagen gel contraction is stimulated by PDGF. Exp Cell Res 1990; 186:264.</a></li><li><a class="nounderline abstract_t">Stummvoll GH, Aringer M, Grisar J, et al. Increased transendothelial migration of scleroderma lymphocytes. Ann Rheum Dis 2004; 63:569.</a></li><li><a class="nounderline abstract_t">York MR. Novel insights on the role of the innate immune system in systemic sclerosis. Expert Rev Clin Immunol 2011; 7:481.</a></li><li><a class="nounderline abstract_t">Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2011; 8:42.</a></li><li><a class="nounderline abstract_t">Al-Adwi Y, Westra J, van Goor H, et al. Macrophages as determinants and regulators of fibrosis in systemic sclerosis. Rheumatology (Oxford) 2023; 62:535.</a></li><li><a class="nounderline abstract_t">Reveille JD, Solomon DH, American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003; 49:399.</a></li><li><a class="nounderline abstract_t">Tan FK, Arnett FC, Antohi S, et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol 1999; 163:1066.</a></li><li><a class="nounderline abstract_t">Bunn CC, Black CM. Systemic sclerosis: an autoantibody mosaic. Clin Exp Immunol 1999; 117:207.</a></li><li><a class="nounderline abstract_t">Hu PQ, Fertig N, Medsger TA Jr, Wright TM. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003; 48:1363.</a></li><li><a class="nounderline abstract_t">Casciola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 1997; 185:71.</a></li><li><a class="nounderline abstract_t">Lunardi C, Bason C, Navone R, et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 2000; 6:1183.</a></li><li><a class="nounderline abstract_t">Chizzolini C, Raschi E, Rezzonico R, et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002; 46:1602.</a></li><li><a class="nounderline abstract_t">Hénault J, Tremblay M, Clément I, et al. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum 2004; 50:3265.</a></li><li><a class="nounderline abstract_t">Hénault J, Robitaille G, Senécal JL, Raymond Y. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 2006; 54:963.</a></li><li><a class="nounderline abstract_t">Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354:2667.</a></li><li><a class="nounderline abstract_t">Dragun D, Distler JH, Riemekasten G, Distler O. Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology. Arthritis Rheum 2009; 60:907.</a></li><li><a class="nounderline abstract_t">Riemekasten G, Philippe A, Näther M, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011; 70:530.</a></li><li><a class="nounderline abstract_t">Cabral-Marques O, Marques A, Giil LM, et al. GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. Nat Commun 2018; 9:5224.</a></li><li><a class="nounderline abstract_t">Cepeda EJ, Reveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol 2004; 16:723.</a></li><li><a class="nounderline abstract_t">Sato S, Kodera M, Hasegawa M, et al. Antinucleosome antibody is a major autoantibody in localized scleroderma. Br J Dermatol 2004; 151:1182.</a></li><li><a class="nounderline abstract_t">Assous N, Allanore Y, Batteux F, et al. Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol 2005; 23:199.</a></li><li><a class="nounderline abstract_t">Arnett FC. Is scleroderma an autoantibody mediated disease? Curr Opin Rheumatol 2006; 18:579.</a></li><li><a class="nounderline abstract_t">Clark KEN, Campochiaro C, Csomor E, et al. Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2021; 80:1584.</a></li><li><a class="nounderline abstract_t">Inamo J. Association of differentially expressed genes and autoantibody type in patients with systemic sclerosis. Rheumatology (Oxford) 2021; 60:929.</a></li><li><a class="nounderline abstract_t">Ruzek MC, Jha S, Ledbetter S, et al. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 2004; 50:1319.</a></li><li><a class="nounderline abstract_t">Chakravarty E. Pre-disease pregnancy complications and systemic sclerosis: pathogenic or pre-clinical? Arthritis Res Ther 2012; 14:102.</a></li><li><a class="nounderline abstract_t">Artlett CM, Smith JB, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998; 338:1186.</a></li><li><a class="nounderline abstract_t">Nelson JL, Furst DE, Maloney S, et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 1998; 351:559.</a></li><li><a class="nounderline abstract_t">Evans PC, Lambert N, Maloney S, et al. Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. Blood 1999; 93:2033.</a></li><li><a class="nounderline abstract_t">Artlett CM, Cox LA, Jimenez SA. Detection of cellular microchimerism of male or female origin in systemic sclerosis patients by polymerase chain reaction analysis of HLA-Cw antigens. Arthritis Rheum 2000; 43:1062.</a></li><li><a class="nounderline abstract_t">Johnson KL, Nelson JL, Furst DE, et al. Fetal cell microchimerism in tissue from multiple sites in women with systemic sclerosis. Arthritis Rheum 2001; 44:1848.</a></li><li><a class="nounderline abstract_t">Nelson JL. Microchimerism and autoimmune disease. N Engl J Med 1998; 338:1224.</a></li><li><a class="nounderline abstract_t">Bashkin P, Doctrow S, Klagsbrun M, et al. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 1989; 28:1737.</a></li><li><a class="nounderline abstract_t">Leroy EC. Connective tissue synthesis by scleroderma skin fibroblasts in cell culture. J Exp Med 1972; 135:1351.</a></li><li><a class="nounderline abstract_t">Uitto J, Bauer EA, Eisen AZ. Scleroderma: increased biosynthesis of triple-helical type I and type III procollagens associated with unaltered expression of collagenase by skin fibroblasts in culture. J Clin Invest 1979; 64:921.</a></li><li><a class="nounderline abstract_t">Abraham D, Lupoli S, McWhirter A, et al. Expression and function of surface antigens on scleroderma fibroblasts. Arthritis Rheum 1991; 34:1164.</a></li><li><a class="nounderline abstract_t">Shi-Wen X, Panesar M, Vancheeswaran R, et al. Expression and shedding of intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 by normal and scleroderma fibroblasts. Effects of interferon-gamma, tumor necrosis factor alpha, and estrogen. Arthritis Rheum 1994; 37:1689.</a></li><li><a class="nounderline abstract_t">LeRoy EC, Mercurio S, Sherer GK. Replication and phenotypic expression of control and scleroderma human fibroblasts: responses to growth factors. Proc Natl Acad Sci U S A 1982; 79:1286.</a></li><li><a class="nounderline abstract_t">Dziadzio M, Smith RE, Abraham DJ, et al. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology (Oxford) 2005; 44:1518.</a></li><li><a class="nounderline abstract_t">Higley H, Persichitte K, Chu S, et al. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994; 37:278.</a></li><li><a class="nounderline abstract_t">Corrin B, Butcher D, McAnulty BJ, et al. Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 1994; 24:145.</a></li><li><a class="nounderline abstract_t">Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987; 247:597.</a></li><li><a class="nounderline abstract_t">Krieg T, Meurer M. Systemic scleroderma. Clinical and pathophysiologic aspects. J Am Acad Dermatol 1988; 18:457.</a></li><li><a class="nounderline abstract_t">Smith EA, LeRoy EC. A possible role for transforming growth factor-beta in systemic sclerosis. J Invest Dermatol 1990; 95:125S.</a></li><li><a class="nounderline abstract_t">McWhirter A, Colosetti P, Rubin K, et al. Collagen type I is not under autocrine control by transforming growth factor-beta 1 in normal and scleroderma fibroblasts. Lab Invest 1994; 71:885.</a></li><li><a class="nounderline abstract_t">Yamakage A, Kikuchi K, Smith EA, et al. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 1992; 175:1227.</a></li><li><a class="nounderline abstract_t">Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 2001; 44:474.</a></li><li><a class="nounderline abstract_t">Kubo M, Ihn H, Yamane K, Tamaki K. Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 2001; 44:731.</a></li><li><a class="nounderline abstract_t">Asano Y, Ihn H, Yamane K, et al. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 2004; 113:253.</a></li><li><a class="nounderline abstract_t">Dong C, Zhu S, Wang T, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 2002; 99:3908.</a></li><li><a class="nounderline abstract_t">Leask A, Abraham DJ, Finlay DR, et al. Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum 2002; 46:1857.</a></li><li><a class="nounderline abstract_t">Gay S, Trabandt A, Moreland LW, Gay RE. Growth factors, extracellular matrix, and oncogenes in scleroderma. Arthritis Rheum 1992; 35:304.</a></li><li><a class="nounderline abstract_t">Leask A, Holmes A, Abraham DJ. Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis. Curr Rheumatol Rep 2002; 4:136.</a></li><li><a class="nounderline abstract_t">Dziadzio M, Usinger W, Leask A, et al. N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. QJM 2005; 98:485.</a></li><li><a class="nounderline abstract_t">Holmes A, Abraham DJ, Sa S, et al. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 2001; 276:10594.</a></li><li><a class="nounderline abstract_t">Shi-wen X, Stanton LA, Kennedy L, et al. CCN2 is necessary for adhesive responses to transforming growth factor-beta1 in embryonic fibroblasts. J Biol Chem 2006; 281:10715.</a></li><li><a class="nounderline abstract_t">Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016; 387:2630.</a></li><li><a class="nounderline abstract_t">Khan K, Xu S, Nihtyanova S, et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 2012; 71:1235.</a></li><li><a class="nounderline abstract_t">De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013; 40:435.</a></li><li><a class="nounderline abstract_t">Feghali CA, Bost KL, Boulware DW, Levy LS. Human recombinant interleukin-4 induces proliferation and interleukin-6 production by cultured human skin fibroblasts. Clin Immunol Immunopathol 1992; 63:182.</a></li><li><a class="nounderline abstract_t">Kawaguchi Y. IL-1 alpha gene expression and protein production by fibroblasts from patients with systemic sclerosis. Clin Exp Immunol 1994; 97:445.</a></li><li><a class="nounderline abstract_t">Denton CP, Ong VH, Xu S, et al. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis 2018; 77:1362.</a></li><li><a class="nounderline abstract_t">O'Reilly S, Ciechomska M, Cant R, et al. Interleukin-6, its role in fibrosing conditions. Cytokine Growth Factor Rev 2012; 23:99.</a></li><li><a class="nounderline abstract_t">Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999; 103:1253.</a></li><li><a class="nounderline abstract_t">Kawaguchi Y, McCarthy SA, Watkins SC, Wright TM. Autocrine activation by interleukin 1alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts. J Rheumatol 2004; 31:1946.</a></li><li><a class="nounderline abstract_t">Aden N, Nuttall A, Shiwen X, et al. Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis. J Invest Dermatol 2010; 130:2191.</a></li><li><a class="nounderline abstract_t">Distler JH, Jüngel A, Caretto D, et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 2006; 54:214.</a></li><li><a class="nounderline abstract_t">Allanore Y, Wung P, Soubrane C, et al. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2020; 79:1600.</a></li><li><a class="nounderline abstract_t">Aidoudi S, Bujakowska K, Kieffer N, Bikfalvi A. The CXC-chemokine CXCL4 interacts with integrins implicated in angiogenesis. PLoS One 2008; 3:e2657.</a></li><li><a class="nounderline abstract_t">Romagnani P, Maggi L, Mazzinghi B, et al. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol 2005; 116:1372.</a></li><li><a class="nounderline abstract_t">van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014; 370:433.</a></li><li><a class="nounderline abstract_t">Rönnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008; 17:394.</a></li><li><a class="nounderline abstract_t">van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007; 66:1008.</a></li><li><a class="nounderline abstract_t">Eloranta ML, Franck-Larsson K, Lövgren T, et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010; 69:1396.</a></li><li><a class="nounderline abstract_t">Kim D, Peck A, Santer D, et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum 2008; 58:2163.</a></li><li><a class="nounderline abstract_t">Carulli MT, Ong VH, Ponticos M, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 2005; 52:3772.</a></li><li><a class="nounderline abstract_t">Ong VH, Evans LA, Shiwen X, et al. Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum 2003; 48:1979.</a></li><li><a class="nounderline abstract_t">Antonelli A, Ferri C, Fallahi P, et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis--a longitudinal study. Rheumatology (Oxford) 2008; 47:45.</a></li><li><a class="nounderline abstract_t">Tiev KP, Hua-Huy T, Kettaneh A, et al. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis. Eur Respir J 2011; 38:1355.</a></li><li><a class="nounderline abstract_t">Schmidt K, Martinez-Gamboa L, Meier S, et al. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 2009; 11:R111.</a></li><li><a class="nounderline abstract_t">Volkmann ER, Tashkin DP, Kuwana M, et al. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis Rheumatol 2019; 71:2059.</a></li><li><a class="nounderline abstract_t">Allanore Y, Distler O, Jagerschmidt A, et al. Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study. Arthritis Rheumatol 2018; 70:1634.</a></li><li><a class="nounderline abstract_t">Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992; 35:67.</a></li><li><a class="nounderline abstract_t">Takemura H, Suzuki H, Yoshizaki K, et al. Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosis. Arthritis Rheum 1992; 35:940.</a></li><li><a class="nounderline abstract_t">Furuse S, Fujii H, Kaburagi Y, et al. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J Rheumatol 2003; 30:1524.</a></li><li><a class="nounderline abstract_t">Kurasawa K, Hirose K, Sano H, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43:2455.</a></li><li><a class="nounderline abstract_t">Shi-Wen X, Denton CP, McWhirter A, et al. Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. Arthritis Rheum 1997; 40:1237.</a></li><li class="breakAll">Korn JH, Thrall RS, Wilbur DC, et al. Fibroblast heterogeneity: clonal selection of fibroblasts as a model for fibrotic disease. In: Pulmonary fibroblast heterogeneity, Phipps RP (Ed), CRC Press, Boca Raton, Florida 1992.</li><li><a class="nounderline abstract_t">Kähäri VM, Sandberg M, Kalimo H, et al. Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. J Invest Dermatol 1988; 90:664.</a></li><li><a class="nounderline abstract_t">Scharffetter K, Lankat-Buttgereit B, Krieg T. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988; 18:9.</a></li><li><a class="nounderline abstract_t">Wei J, Ghosh AK, Sargent JL, et al. PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010; 5:e13778.</a></li><li><a class="nounderline abstract_t">Palumbo-Zerr K, Zerr P, Distler A, et al. Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis. Nat Med 2015; 21:150.</a></li><li><a class="nounderline abstract_t">Ruzehaji N, Frantz C, Ponsoye M, et al. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Ann Rheum Dis 2016; 75:2175.</a></li><li><a class="nounderline abstract_t">Gilbane AJ, Denton CP, Holmes AM. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther 2013; 15:215.</a></li><li><a class="nounderline abstract_t">Denton CP, Khan K, Hoyles RK, et al. Inducible lineage-specific deletion of TbetaRII in fibroblasts defines a pivotal regulatory role during adult skin wound healing. J Invest Dermatol 2009; 129:194.</a></li><li><a class="nounderline abstract_t">Hoyles RK, Derrett-Smith EC, Khan K, et al. An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor β receptor. Am J Respir Crit Care Med 2011; 183:249.</a></li><li><a class="nounderline abstract_t">Denton CP, Ong VH. Targeted therapies for systemic sclerosis. Nat Rev Rheumatol 2013; 9:451.</a></li><li><a class="nounderline abstract_t">Trojanowska M, Wu LT, LeRoy EC. Elevated expression of c-myc proto-oncogene in scleroderma fibroblasts. Oncogene 1988; 3:477.</a></li><li><a class="nounderline abstract_t">Jimenez SA, Gaidarova S, Saitta B, et al. Role of protein kinase C-delta in the regulation of collagen gene expression in scleroderma fibroblasts. J Clin Invest 2001; 108:1395.</a></li><li><a class="nounderline abstract_t">Shiwen X, Stratton R, Nikitorowicz-Buniak J, et al. A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related Fibrosis. PLoS One 2015; 10:e0126015.</a></li><li><a class="nounderline abstract_t">Bhattacharyya S, Tamaki Z, Wang W, et al. FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Sci Transl Med 2014; 6:232ra50.</a></li><li><a class="nounderline abstract_t">Wallis DD, Tan FK, Kielty CM, et al. Abnormalities in fibrillin 1-containing microfibrils in dermal fibroblast cultures from patients with systemic sclerosis (scleroderma). Arthritis Rheum 2001; 44:1855.</a></li><li><a class="nounderline abstract_t">Tan FK, Stivers DN, Foster MW, et al. Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population. Arthritis Rheum 1998; 41:1729.</a></li><li><a class="nounderline abstract_t">Siracusa LD, McGrath R, Ma Q, et al. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 1996; 6:300.</a></li><li><a class="nounderline abstract_t">Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54:2271.</a></li><li><a class="nounderline abstract_t">Clark KEN, Csomor E, Campochiaro C, et al. Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study. Lancet Rheumatol 2022; 7:E507.</a></li><li><a class="nounderline abstract_t">Valenzi E, Bulik M, Tabib T, et al. Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease. Ann Rheum Dis 2019; 78:1379.</a></li><li><a class="nounderline abstract_t">Gur C, Wang SY, Sheban F, et al. LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma. Cell 2022; 185:1373.</a></li><li><a class="nounderline abstract_t">Ivarsson M, McWhirter A, Black CM, Rubin K. Impaired regulation of collagen pro-alpha 1(I) mRNA and change in pattern of collagen-binding integrins on scleroderma fibroblasts. J Invest Dermatol 1993; 101:216.</a></li><li><a class="nounderline abstract_t">Eckes B, Mauch C, Hüppe G, Krieg T. Downregulation of collagen synthesis in fibroblasts within three-dimensional collagen lattices involves transcriptional and posttranscriptional mechanisms. FEBS Lett 1993; 318:129.</a></li><li><a class="nounderline abstract_t">Takeda K, Hatamochi A, Ueki H, et al. Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol 1994; 103:359.</a></li><li><a class="nounderline abstract_t">Kirk TZ, Mark ME, Chua CC, et al. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem 1995; 270:3423.</a></li><li><a class="nounderline abstract_t">Hebbar M, Peyrat JP, Hornez L, et al. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 2000; 43:889.</a></li></ol></div><div id="topicVersionRevision">Topic 7554 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7595885" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The aetiopathogenesis of systemic sclerosis: thick skin--thin hypotheses. The Parkes Weber Lecture 1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8676631" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7954195" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Lymphocyte modulation of fibroblast function in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7954196" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The fibroblast in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21779181" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20383147" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1750799" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The endothelium: its role in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7609754" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Endothelins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10943881" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1859492" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1978025" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1464869" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Significance of plasma endothelin-1 levels in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7837147" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7525957" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Localization of endothelin-1 and its binding sites in scleroderma skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10739336" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Autoimmunity and vascular involvement in systemic sclerosis (SSc).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10914853" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Exhaled nitric oxide in systemic sclerosis: relationships with lung involvement and pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10817563" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16385516" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Variations of neuronal nitric oxide synthase in systemic sclerosis skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3977420" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Endothelial cell cytotoxicity in inflammatory vascular diseases--the possible role of oxidised lipoproteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7639801" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8670323" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449367" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16399843" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15313361" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Defective vasculogenesis in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8550821" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11083280" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13130480" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16802364" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9073533" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17907150" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Antiangiogenic plasma activity in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10685805" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1974032" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Adhesion receptors of the immune system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10551675" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Abnormalities of adhesion molecules and chemokines in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1720957" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1371389" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1430352" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8099861" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7687701" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9893759" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8542206" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16418202" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1622415" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1517881" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sequential dermal microvascular and perivascular changes in the development of scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1555235" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Integrins: versatility, modulation, and signaling in cell adhesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2298242" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Beta 1 integrin-mediated collagen gel contraction is stimulated by PDGF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15082489" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Increased transendothelial migration of scleroderma lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21790291" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Novel insights on the role of the innate immune system in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22025123" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35861385" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Macrophages as determinants and regulators of fibrosis in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12794797" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10395706" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10444248" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Systemic sclerosis: an autoantibody mosaic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12746909" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996243" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11017152" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115192" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15476238" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16508979" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16790699" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19333918" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21081526" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Involvement of functional autoantibodies against vascular receptors in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30523250" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15577611" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15606513" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Antinucleosome antibody is a major autoantibody in localized scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15895890" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17053501" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Is scleroderma an autoantibody mediated disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34230031" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32911535" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Association of differentially expressed genes and autoantibody type in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15077316" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22313964" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pre-disease pregnancy complications and systemic sclerosis: pathogenic or pre-clinical?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9554859" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9492775" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Microchimerism and HLA-compatible relationships of pregnancy in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10068676" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10817560" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Detection of cellular microchimerism of male or female origin in systemic sclerosis patients by polymerase chain reaction analysis of HLA-Cw antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11508438" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Fetal cell microchimerism in tissue from multiple sites in women with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9554866" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Microchimerism and autoimmune disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2541764" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4260235" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Connective tissue synthesis by scleroderma skin fibroblasts in cell culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/90059" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Scleroderma: increased biosynthesis of triple-helical type I and type III procollagens associated with unaltered expression of collagenase by skin fibroblasts in culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1718289" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Expression and function of surface antigens on scleroderma fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7526872" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Expression and shedding of intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 by normal and scleroderma fibroblasts. Effects of interferon-gamma, tumor necrosis factor alpha, and estrogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6461858" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Replication and phenotypic expression of control and scleroderma human fibroblasts: responses to growth factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16159952" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7510487" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8181807" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3501287" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3280619" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Systemic scleroderma. Clinical and pathophysiologic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2258629" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A possible role for transforming growth factor-beta in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7807970" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Collagen type I is not under autocrine control by transforming growth factor-beta 1 in normal and scleroderma fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1314885" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11229480" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11263790" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14722617" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904440" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Deficient Smad7 expression: a putative molecular defect in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12124870" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1536668" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Growth factors, extracellular matrix, and oncogenes in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11890879" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15955800" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11152469" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16484225" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : CCN2 is necessary for adhesive responses to transforming growth factor-beta1 in embryonic fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27156934" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22586157" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23378460" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1611720" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Human recombinant interleukin-4 induces proliferation and interleukin-6 production by cultured human skin fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8082299" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : IL-1 alpha gene expression and protein production by fibroblasts from patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29853453" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22561547" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Interleukin-6, its role in fibrosing conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10225968" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15468358" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Autocrine activation by interleukin 1alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20445556" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16385517" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32963047" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18648521" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : The CXC-chemokine CXCL4 interacts with integrins implicated in angiogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16337473" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24350901" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18490415" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : The innate immune system in SLE: type I interferons and dendritic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17223656" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472592" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Type I interferon system activation and association with disease manifestations in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18576347" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16320328" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12847692" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18077490" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis--a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21778167" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19615053" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31233287" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29732731" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1731816" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1642659" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12858452" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11083268" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Increased interleukin-17 production in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9214423" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9214423" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3361141" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3130266" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21072170" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : PPARγdownregulation by TGFßin fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25581517" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Orphan nuclear receptor NR4A1 regulates transforming growth factor-βsignaling and fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26961294" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23796020" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18563179" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Inducible lineage-specific deletion of TbetaRII in fibroblasts defines a pivotal regulatory role during adult skin wound healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20709822" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factorβreceptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23567456" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Targeted therapies for systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3078955" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Elevated expression of c-myc proto-oncogene in scleroderma fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11696585" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Role of protein kinase C-delta in the regulation of collagen gene expression in scleroderma fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25955164" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24739758" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11508439" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Abnormalities in fibrillin 1-containing microfibrils in dermal fibroblast cultures from patients with systemic sclerosis (scleroderma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9778214" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8723723" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16802366" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31405848" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35381199" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8345224" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Impaired regulation of collagen pro-alpha 1(I) mRNA and change in pattern of collagen-binding integrins on scleroderma fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8440370" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Downregulation of collagen synthesis in fibroblasts within three-dimensional collagen lattices involves transcriptional and posttranscriptional mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8077701" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Decreased collagenase expression in cultured systemic sclerosis fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7852429" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10765935" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
